PRODUCT LITERATURE

Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, doubleblind study

---

Inosine pranobex (Isoprinosine®) is an immunomodulatory drug approved in several countries for the treatment of viral infections. This study compared the efficacy and safety of inosine pranobex versus placebo
in subjects with clinically diagnosed influenza-like illness, including subjects with laboratory-confirmed acute
respiratory viral infections. Subgroup analyses evaluated the efficacy of inosine pranobex compared to placebo
in otherwise healthy (without related ongoing disease) subjects that were less than 50 years of age and healthy
subjects that were at least 50 years of age. The effect of body mass index (BMI) was evaluated in subjects less
than 50 years of age.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Moprin

Specific Detail Info

Beran et al. BMC Infectious Diseases (2016) 16:648

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment